Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ: NTLA )

9.120 -0.100 (-1.08%)
Streaming Delayed Price Updated: 1:19 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to... 
Via Benzinga
Intellia Seeks To Raise $400M Via Equity
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to... 
Via Benzinga
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know
An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ: 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride
Intellia's recent press release reveals first-of-its-kind clinical results for genome editing technology, leading NTLA stock skyward. 
Via InvestorPlace
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Beam Therapeutics Jumped Today
A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution. 
Via The Motley Fool
Why Editas Medicine Stock Is Jumping Today
Good news for Intellia was viewed as good news for Editas. 
Via The Motley Fool
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Why Intellia Therapeutics Stock Is Skyrocketing Today
The company reported promising interim trial results for its CRISPR gene-editing candidate. 
Via The Motley Fool
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 118 stocks hit new 52-week highs. Highlights: The company with the largest market cap to set a new 52-week high was Microsoft... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Is Soaring Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Barclays raised the price target for Accenture plc (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Dow Jones surged more than 230 points in the previous session. The S&P 500 index also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Expert Ratings For Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1... 
Via Benzinga
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
From Blackstone
Via Business Wire
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
This Genetics Stock Could Have a Bright Future
Here's one genetics play that you might want to put on your radar. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.